Abstract
Background
In animal models, pretreatment with angiotensin‐converting enzyme inhibitor (ACEI) can reduce no‐reflow. In the present study, we investigated whether pretreatment with ACEI may prevent no‐reflow in patients who underwent primary coronary intervention for AMI.
Method and Results
A total of 259 consecutive patients who underwent primary angioplasty for a first AMI were studied. No‐reflow was defined as a TIMI flow grade < 3. The no‐reflow phenomenon was found in 33 of 259 patients. There were no significant differences in clinical characteristics between the patients with and without ACEI pretreatment. However, the 47 patients receiving chronic ACEI treatment before admission had lower incidence of the no‐reflow than those without it (4.2 and 14.6%, p < 0.05). Multivariable logistic regression analysis revealed that absence of ACEI pretreatment was a significant predictor of the no‐reflow along with absence of preinfarction angina, complete occlusion of the culprit lesion, high‐burden thrombus, ejection fraction on admission, number of Q‐waves, absence of statin pretreatment, and anterior AMI.
Conclusion
Pretreatment with ACEI could preserve the microvascular integrity after acute myocardial infarction in humans. Copyright © 2007 Wiley Periodicals, Inc.
Keywords: myocardial infarction, reperfusion, angiotensin‐converting enzyme inhibitor
Full Text
The Full Text of this article is available as a PDF (231.5 KB).
REFERENCES
- 1. Morishima I, Sone T, Okumura K, Tsuboi H, Kondo J, et al.: Angiographic no‐reflow phenomenon as a predictor of adverse long‐term outcome in patients treated with percutaneous transluminal coronary angioplasty for first acute myocardial infarction. J Am Coll Cardiol 2000; 36: 1202–1209. [DOI] [PubMed] [Google Scholar]
- 2. Ito H, Maruyama A, Iwakura K: Clinical implications of the ‘no‐reflow’ phenomenon: A predictor of complications and left ventricular remodeling in perfused anterior wall myocardial infarction. Circulation 1996; 93: 223–228. [DOI] [PubMed] [Google Scholar]
- 3. Podesser BK, Schirnhofer J, Bernecker OY, Kroner A, Franz M, et al.: Optimizing ischemia/reperfusion in the failing rat heart–improved myocardial protection with acute ACE inhibition. Circulation 2002; 106(12suppl1): I277–I283. [PubMed] [Google Scholar]
- 4. Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, et al.: Pretreatment with fosinopril or valsartan reduces myocardial no‐reflow after acute myocardial infarction and reperfusion. Coron Artery Dis 2006; 17: 463–469. [DOI] [PubMed] [Google Scholar]
- 5. Rentrop K.P, Cohen M, Blanke H, Phillips RA: Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5: 587–592. [DOI] [PubMed] [Google Scholar]
- 6. Yip HK, Chen MC, Chang HW, Hang CL, Hsieh YK, et al.: Angiographic morphologic features of infarct‐related arteries and timely reperfusion in acute myocardial infarction: Predictors of slow‐flow and no‐reflow phenomenon. Chest 2002; 122: 1322–1332. [DOI] [PubMed] [Google Scholar]
- 7. Piana RN, Paik GY, Moscucci M, Cohen D, Gibson CM, et al.: Incidence and treatment of no‐reflow after percutaneous coronary intervention. Circulation 1994; 89: 2514–2518. [DOI] [PubMed] [Google Scholar]
- 8. Air PAMI Study Group. A randomized trial of transfer for primary angioplasty versus thrombolysis in patients with high risk myocardial infarction. J Am Coll Cardiol 2002; 39: 1713–1719. [DOI] [PubMed] [Google Scholar]
- 9. Kloner RA, Ganote CE, Jennings RB: The “no‐reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974; 54: 1496–1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Enseleit F, Hurlimann D, Luscher T: Vascular protective effects of angiotensin converting enzyme inhibitors and their relation to clinical events. J Cardiovasc Pharmacol 2001; 37(suppl 1): S21. [DOI] [PubMed] [Google Scholar]
- 11. Brown N, Douglas V: Angiotensin‐converting enzyme inhibitors. Circulation 1998; 97: 1411–1420. [DOI] [PubMed] [Google Scholar]
- 12. Kishi Y, Ohta S, Kasuya N, Sakita SY, Ashikaqa T, et al.: Perindopril augments ecto‐ATP diphosphohydrolase activity and enhances endothelial anti‐platelet function in human umbilical vein endothelial cells. J Hypertens 2003; 21: 1347–1353. [DOI] [PubMed] [Google Scholar]
- 13. Fogari R, Mugellini A, Zoppi A, Corradi L, Preti P, et al.: Losartan and perindopril effects on plasma plasminogen activator inhibitor‐1 and fibrinogen in hypertensive type 2 diabetic patients. Am J Hypertens 2002; 15: 316–332. [DOI] [PubMed] [Google Scholar]
- 14. Fennessy PA, Campbell JH, Mendelsohn FAO, Campbell GR: Angiotensin‐converting enzyme inhibitors and atherosclerosis: Relevance of animal models to human disease. Clin Pharmacol Physiol 1996; 23(suppl 1): S30–S32. [DOI] [PubMed] [Google Scholar]
- 15. Mehta RH, Harjai KJ, Cox D, Stone GW, Brodie B, et al.: Clinical and angiographic correlates and outcomes of suboptimal coronary flow inpatients with acute myocardial infarction undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2003; 42: 1739–1746. [DOI] [PubMed] [Google Scholar]
- 16. Iwakura K, Ito H, Kawano S, Okamura A, Kurotobi T, et al.: Chronic pre‐treatment of statins is associated with the reduction of the no‐reflow phenomenon in the patients with reperfused acute myocardial infarction. Eur Heart J 2006; 27: 534–539. [DOI] [PubMed] [Google Scholar]